Literature DB >> 8534583

Positron emission tomography with 4-[18F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys.

N Hayase1, K Tomiyoshi, K Watanabe, S Horikoshi, T Shibasaki, C Ohye.   

Abstract

PET imaging studies with 4-[18F]fluoro-L-m-tyrosine (FMT) in normal macaca monkeys showed selective accumulations of radioactivity in the striatum with time. In monkeys rendered hemiparkinsonian by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), FMT uptake was eliminated in the lesioned striatum. FMT-PET studies were able to detect dopaminergic terminals in both normal and hemiparkinsonian monkeys, and clearly showed a reduction in aromatic L-amino acid decarboxylase (AAAD) activities in the MPTP-lesioned striatum. These results show that FMT is promising as a PET tracer for the evaluation of central dopaminergic systems in parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534583     DOI: 10.1007/bf03165037

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  24 in total

Review 1.  Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Authors:  H C Guldberg; C A Marsden
Journal:  Pharmacol Rev       Date:  1975-06       Impact factor: 25.468

2.  Motor and nonmotor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion.

Authors:  J S Schneider; W W McLaughlin; D P Roeltgen
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

3.  Substrate specificity and other properties of DOPA decarboxylase from guinea pig kidneys.

Authors:  K Srinivasan; J Awapara
Journal:  Biochim Biophys Acta       Date:  1978-10-12

4.  4-[18F]fluoro-L-m-tyrosine: an L-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography.

Authors:  W P Melega; M M Perlmutter; A Luxen; C H Nissenson; S T Grafton; S C Huang; M E Phelps; J R Barrio
Journal:  J Neurochem       Date:  1989-07       Impact factor: 5.372

5.  Action of m-tyrosine in experimental models: evidence for possible antiparkinsonian activity.

Authors:  U Ungerstedt; K Fuxe; M Goldstein; A Battista; M Ogawa; B Anagnoste
Journal:  Eur J Pharmacol       Date:  1973-02       Impact factor: 4.432

6.  The metabolism of L-m-tyrosine in man.

Authors:  V Fell; A M Greenway; J A Hoskins
Journal:  Biochem Med       Date:  1979-10

7.  6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.

Authors:  J R Barrio; S C Huang; W P Melega; D C Yu; J M Hoffman; J S Schneider; N Satyamurthy; J C Mazziotta; M E Phelps
Journal:  J Neurosci Res       Date:  1990-12       Impact factor: 4.164

8.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease.

Authors:  D B Calne; J W Langston; W R Martin; A J Stoessl; T J Ruth; M J Adam; B D Pate; M Schulzer
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

9.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  K S Bankiewicz; E H Oldfield; C C Chiueh; J L Doppman; D M Jacobowitz; I J Kopin
Journal:  Life Sci       Date:  1986-07-07       Impact factor: 5.037

10.  Radiobrominated m-tyrosine analog as potential CNS L-dopa pet tracer.

Authors:  O T De Jesus; J Mukherjee
Journal:  Biochem Biophys Res Commun       Date:  1988-02-15       Impact factor: 3.575

View more
  1 in total

1.  An in vivo microdialysis study of striatal 6-[18F]fluoro-L-m-tyrosine metabolism.

Authors:  S Jordan; K S Bankiewicz; J L Eberling; H F VanBrocklin; J P O'Neil; W J Jagust
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.